PL1951283T3 - Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika - Google Patents

Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Info

Publication number
PL1951283T3
PL1951283T3 PL06812748T PL06812748T PL1951283T3 PL 1951283 T3 PL1951283 T3 PL 1951283T3 PL 06812748 T PL06812748 T PL 06812748T PL 06812748 T PL06812748 T PL 06812748T PL 1951283 T3 PL1951283 T3 PL 1951283T3
Authority
PL
Poland
Prior art keywords
ovarian cancer
treating
pharmaceutical composition
glycoproteins
polypeptides
Prior art date
Application number
PL06812748T
Other languages
English (en)
Inventor
Bennink Herman Jan Tijmen Coelingh
Visser Monique
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of PL1951283T3 publication Critical patent/PL1951283T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/892Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06812748T 2005-11-16 2006-11-16 Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika PL1951283T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73687705P 2005-11-16 2005-11-16
EP05110819 2005-11-16
PCT/NL2006/050289 WO2007058536A1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer
EP06812748A EP1951283B1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer

Publications (1)

Publication Number Publication Date
PL1951283T3 true PL1951283T3 (pl) 2010-12-31

Family

ID=37686152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06812748T PL1951283T3 (pl) 2005-11-16 2006-11-16 Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Country Status (8)

Country Link
US (1) US7968514B2 (pl)
EP (1) EP1951283B1 (pl)
CN (1) CN101365473B (pl)
AT (1) ATE473756T1 (pl)
CA (1) CA2630175C (pl)
DE (1) DE602006015508D1 (pl)
PL (1) PL1951283T3 (pl)
WO (1) WO2007058536A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
WO2013040071A2 (en) * 2011-09-15 2013-03-21 University Of Southern California Sperm protein as a detection biomarker of early stage ovarian cancer
CN104804075A (zh) * 2014-01-24 2015-07-29 中南大学 变异的人卵透明带蛋白1和突变基因及检测方法和应用
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2020048924A1 (en) 2018-09-03 2020-03-12 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
JPH0799974A (ja) * 1993-10-05 1995-04-18 Tonen Corp ヒト卵透明帯−2蛋白質をコードするdna
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US6455041B1 (en) 1998-11-17 2002-09-24 Bonita S. Dunbar Immunogenic epitopes of the human zona pellucida protein (ZP1)
AU5909500A (en) 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Method and composition for affecting reproductive systems
US6455941B1 (en) 2001-01-03 2002-09-24 Advanced Semiconductor Engineering, Inc. Chip scale package
US20090252721A1 (en) * 2003-09-18 2009-10-08 Thomas Buschmann Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer

Also Published As

Publication number Publication date
CN101365473B (zh) 2013-04-03
CN101365473A (zh) 2009-02-11
DE602006015508D1 (de) 2010-08-26
ATE473756T1 (de) 2010-07-15
EP1951283B1 (en) 2010-07-14
EP1951283A1 (en) 2008-08-06
US20090060931A1 (en) 2009-03-05
CA2630175C (en) 2018-10-23
WO2007058536A1 (en) 2007-05-24
CA2630175A1 (en) 2007-05-24
US7968514B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2006081826A3 (en) Survivin peptide vaccine
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12012502272A1 (en) Biological materials related to her3
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
IL187293A0 (en) Recombinant n-glycosylated proteins from procaryotic cells
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12021551656A1 (en) Pharmaceutical delivery compositions and uses thereof
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
NZ594268A (en) Grass peptides for vaccine
EP4406613A3 (en) Immunogenic arginase peptides
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
PL1951283T3 (pl) Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
PH12021551372A1 (en) Human alpha-galactosidase variants
WO2012026820A3 (en) Immunotherapeutic method for treating prostate cancer
PT1290160E (pt) Polipeptideos pellino humanos
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2004053092A3 (en) Human pellino polypeptides
WO2016080830A3 (en) Immunotherapeutic method for treating pancreatic cancer